GSK5182 suppresses osteoclastogenic marker expression. (A and B) We cultured BMMs with RANKL and M-CSF in the absence or presence of GSK5182 (10 μM) for the indicated times. We did real-time PCR (A) or immunoblotting (B) to assess the expression of the indicated genes. *P < 0.05, **P < 0.001 vs. control. (C) We cultured BMMs with M-CSF in the absence (-) or presence (+) of RANKL with various GSK5182 concentrations for 24 h. Whole-cell lysates were subjected to immunoblotting to detect c-Fos. (D) RANK protein expression in cells treated with GSK5182 (10 μM) on the indicated days.